Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links

Search Orphan Drug Designations and Approvals

-

Marketing approved:
Generic Name:	olaparib
Trade Name:	Lynparza
Date Designated:	10/16/2013
Orphan Designation:	Treatment of ovarian cancer
Orphan Designation Status:	Designated/Approved
Sponsor:	AstraZeneca Pharmaceuticals LP 1800 Concord Pike P. O. Box 8355 Wilmington, Delaware 19803 United States The sponsor address listed is the last reported by the sponsor to OOPD.

1	Generic Name:	olaparib
	Trade Name:	Lynparza
	Marketing Approval Date:	12/19/2014
	Approved Labeled Indication:	Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy
	Exclusivity End Date:	12/19/2021
	Exclusivity Protected Indication* :	Use as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy

2	Generic Name:	olaparib
	Trade Name:	Lynparza
	Marketing Approval Date:	08/17/2017
	Approved Labeled Indication:	Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
	Exclusivity End Date:	08/17/2024
	Exclusivity Protected Indication* :	Maintenance treatment of adult patients with recurrent epithelial ovarian cancer, who are in a complete or partial response to platinum-based chemotherapy.

3	Generic Name:	olaparib
	Trade Name:	Lynparza
	Marketing Approval Date:	12/19/2018
	Approved Labeled Indication:	Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.
	Exclusivity End Date:	12/19/2025
	Exclusivity Protected Indication* :	Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian cancer who are in complete or partial response to first-line platinum based chemotherapy.

4	Generic Name:	olaparib
	Trade Name:	Lynparza
	Marketing Approval Date:	05/08/2020
	Approved Labeled Indication:	Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
	Exclusivity End Date:	05/08/2027
	Exclusivity Protected Indication* :	LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.

-

-